Product image of Letybo (Botulinum Toxin Type A) supplied by GNH India

Letybo

Active Ingredient:
Botulinum Toxin Type A
Origin:
EU

Letybo (Botulinum Toxin Type A)

Botulinum toxin type A, the active ingredient in Letybo, is a botulinum toxin presented as a sterile injectable for intramuscular use. By blocking acetylcholine release at the neuromuscular junction, it produces temporary, localized muscle paralysis that helps manage conditions characterized by excessive muscle activity. The effect can last months.

GNH India supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and cold‑chain logistics for this specialized biologic. The company adheres to stringent quality standards.

Manufacturer / TM Owner

Croma Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letybo, a botulinum toxin type A preparation, is used in several neuromuscular and glandular disorders where temporary muscle relaxation or secretion reduction is desired.

  • Cervical dystonia: reduces abnormal neck muscle contractions, improving head posture and pain.
  • Chronic migraine: decreases frequency of migraine attacks when administered prophylactically.
  • Upper limb spasticity: eases muscle stiffness in post‑stroke or cerebral palsy patients.
  • Blepharospasm: relaxes involuntary eyelid muscles, reducing spasms.
  • Severe axillary hyperhidrosis: diminishes excessive sweating by inhibiting sweat gland activity.

How It Works

  • Botulinum toxin type A is a neurotoxin that cleaves SNAP‑25, a protein essential for vesicle fusion in presynaptic nerve terminals. By preventing the release of acetylcholine at the neuromuscular junction, it blocks synaptic transmission, leading to reversible, localized paralysis of the targeted muscle or glandular tissue. The effect persists until new SNAP‑25 proteins are synthesized, typically several weeks to months, after which normal neuromuscular function gradually returns.

Side Effects

Adverse reactions to Letybo are generally related to the injection site and the pharmacologic action of the toxin.

Common Side Effects

  • Injection site pain
  • Bruising or hematoma
  • Headache
  • Flu‑like symptoms
  • Localized muscle weakness

Serious or Rare Side Effects

  • Dysphagia or difficulty swallowing
  • Respiratory compromise
  • Generalized muscle weakness
  • Spread of toxin effect to distant muscles
  • Anaphylactic reaction

Precautions & Warnings

Before using Letybo, clinicians should evaluate patient history and consider specific safety measures.

  • Pregnancy: avoid unless benefits outweigh risks; safety data are limited.
  • Breastfeeding: use with caution; limited information on excretion in milk.
  • Neuromuscular disorders: assess risk of increased weakness in conditions such as myasthenia gravis.
  • Concomitant aminoglycoside or quinolone antibiotics: monitor for enhanced neuromuscular blockade.
  • Allergic reactions: do not administer to patients with known hypersensitivity to botulinum toxin or its excipients.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Letybo may interact with other medicines that affect neuromuscular transmission or toxin metabolism.

Major Interactions (Avoid)

  • Aminoglycoside antibiotics: may potentiate neuromuscular blockade, increasing risk of severe weakness.
  • Quinolone antibiotics: can enhance toxin effect on muscles, leading to respiratory complications.
  • General anesthetics (e.g., succinylcholine): may augment spread of toxin, causing prolonged paralysis.

Moderate Interactions (Monitor Closely)

  • Anticholinergic agents: may reduce therapeutic efficacy of the toxin.
  • Beta‑adrenergic blockers: could alter muscle response, requiring dose adjustment.

Frequently Asked Questions

Letybo is a botulinum toxin type A formulation indicated for conditions that benefit from temporary muscle relaxation or reduced glandular secretion. Recognised uses include cervical dystonia, chronic migraine prophylaxis, upper‑limb spasticity, blepharospasm, and severe axillary hyperhidrosis.

The toxin cleaves the SNAP‑25 protein in presynaptic nerve endings, blocking acetylcholine release at the neuromuscular junction. This inhibition prevents muscle contraction, producing a reversible, localized paralysis that lasts until new SNAP‑25 is synthesized.

The dose is individualized by the prescribing clinician based on the specific indication, size and strength of the target muscle, patient weight, and prior response to treatment. No fixed regimen is provided; the prescriber calculates the appropriate units for each injection site.

Safety data for botulinum toxin type A in pregnancy and lactation are limited. It is generally avoided unless the potential therapeutic benefit justifies the potential risk to the fetus. Breastfeeding mothers should use caution, as the amount transferred in milk is not well defined.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Letybo contains botulinum toxin type A, the same neurotoxin class found in other commercial preparations. Differences may lie in formulation, unit potency, and approved indications. Clinicians choose a product based on clinical experience, regulatory approval in their region, and specific dosing guidelines provided by the manufacturer.

Letybo must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to use, the vial is allowed to reach room temperature and gently mixed if required by the label.

Letybo is administered by a qualified healthcare professional via intramuscular injection. The injection sites and number of units are selected according to the therapeutic indication and individual patient anatomy. Proper aseptic technique and accurate dosing are essential for safety and efficacy.

Serious adverse events include dysphagia, respiratory compromise, generalized muscle weakness, distant spread of toxin effect, and anaphylactic reactions. These risks are rare but require immediate medical attention. Patients should be monitored after injection, especially when treating areas near the airway or neck.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A or any excipients in the formulation. It should also be avoided in patients with active infections at the injection site, certain neuromuscular disorders such as myasthenia gravis, or those taking medications that markedly increase neuromuscular blockade.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Botulinum Toxin Type A

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT